Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 175 Show results per page	View Search Criteria \| Help With Results

Last Modified: 11/1/1997


1.		Phase II/III Pilot Treatment of Pediatric Non-B, Non-T ALL in First Marrow Relapse (SIMAL #8): Intensive Re-Induction and Reconsolidation Chemotherapy with Subsequent Myeloablative Chemoradiotherapy and Rescue with Either Allogeneic or In Vitro-Purged Autologous Marrow (Summary Last Modified 11/97)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Completed				under 21 at relapse				NCI				POG-9410 POG-SIMAL-8


2.		Phase II/III Endocrine Therapy with AG/TMX/HC vs TMX Alone for Metastatic or Recurrent Breast Carcinoma, with AG/HC for Patients with Prior TMX

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				postmenopausal								MAYO-803201


3.		Phase II/III Pilot Study of Endocrine Therapy with Tamoxifen vs Tamoxifen plus Aminoglutethimide in Premenopausal Patients with Metastatic Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				18 to 55				NCI				DFCI-79049 NCI-T84-0176D, T84-0176

Last Modified: 3/14/2007


4.		Phase II/III Randomized Comparison of Up-Front Alternating Chemotherapy vs Up-Front Intensive 6-MP/MTX for Poor Prognosis Childhood ALL

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Completed				1 to 20				NCI				POG-8698

Last Modified: 4/20/2006


5.		Phase II/III Pilot Study of Induction and Intensification Chemotherapy with VP-16, ARA-C, DNR, 5-AZ, and m-AMSA, Using "Modelled" Plasma Drug Concentrations of VP-16 and ARA-C, in Children with Acute Nonlymphocytic Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Completed				under 21				NCI				SJCRH-AML-87 NCI-T86-0203D, T86-0203

Last Modified: 7/11/2007


6.		Phase II/III Randomized Study of MP/MTX vs DCF/MP/MTX in Patients with Relapsed T-ALL or T-NHL Who Achieve Second Remission Following Induction with PVDA (PRED/VCR/DNR/ASP)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				21 and under				NCI				POG-8862

Last Modified: 10/1/1991


7.		Phase II/III Randomized Comparison of VP-16/AMSA vs VP-16/AMSA/AZC in Children with Refractory ANLL (Summary Last Modified 10/91)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				21 and under				NCI				POG-8820

Last Modified: 5/7/2008 First Published: 12/1/1994


8.		Phase III Randomized Study of Twice-Daily vs Standard Daily MP During Continuation Therapy in Children with Standard-Risk Acute Lymphocytic Leukemia: An ALinC #16 Study

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				1 through 21 at diagnosis				NCI				POG-9405 POG-ALINC-16/SR

Last Modified: 5/24/2006


9.		Phase III Randomized Study of Bone Marrow Transplantation vs Prolonged Intensive Chemotherapy Following Remission Re-Induction after Early First Marrow Relapse in Children with Acute Lymphocytic Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				at least 1 + under 20 at diag.				NCI				CCG-1941

Last Modified: 1/1/1996


10.		Phase III Randomized Double-Blind Study of SUR/HC vs Placebo/HC in Metastatic Hormone-Refractory Prostate Carcinoma with Painful Bone Metastases (Summary Last Modified 01/96)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Supportive care, Treatment				Closed				any age				Pharmaceutical / Industry				PD-1003-01 NCI-V94-0598

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute